Microsatellite

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

Retrieved on: 
Monday, January 22, 2024

Dr. Pashtoon Kasi, M.D., Director of Colon Cancer Research at Weill-Cornell Medicine, presented these findings at the ASCO-GI conference.

Key Points: 
  • Dr. Pashtoon Kasi, M.D., Director of Colon Cancer Research at Weill-Cornell Medicine, presented these findings at the ASCO-GI conference.
  • "BOT/BAL's potential impact on colorectal cancer is groundbreaking.
  • BOT/BAL Eliminates Circulating Tumor DNA (ctDNA): patients in the NICHE-1 study were tested for ctDNA, a biomarker closely associated with long-term Disease-Free Survival (DFS).
  • Neoadjuvant BOT/BAL in both MSS and MSI-H CRC resulted in marked tumor regression and robust immune cell infiltration in a very short interval.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Space Flight Laboratory (SFL) Celebrates 25 Years of Developing Smaller Satellites that Outperform Expectations

Retrieved on: 
Monday, October 2, 2023

TORONTO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Space Flight Laboratory (SFL), a developer of comprehensive microspace missions, is celebrating 25 years of building smaller satellites that provide big returns for commercial, government, and research clients.

Key Points: 
  • TORONTO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Space Flight Laboratory (SFL), a developer of comprehensive microspace missions, is celebrating 25 years of building smaller satellites that provide big returns for commercial, government, and research clients.
  • Established in 1998, SFL has built 70 operationally successful satellites recording 270 years in orbit for dozens of distinct microspace missions.
  • SFL will discuss its 25 years of microspace achievements this month at the International Astronautical Congress, InterGEO 2023, and Satellite Innovation 2023 at Silicon Valley Space Week.
  • “For 25 years, SFL has focused on developing quality smaller satellites that achieve high levels of performance at price points affordable for customers in all sectors,” said SFL Director, Dr. Robert E. Zee.

Planet Reports Financial Results for Second Quarter of Fiscal 2024

Retrieved on: 
Thursday, September 7, 2023

Second quarter gross margin was 49%, compared to 48% in the second quarter of fiscal year 2023.

Key Points: 
  • Second quarter gross margin was 49%, compared to 48% in the second quarter of fiscal year 2023.
  • Second quarter Non-GAAP Gross Margin(1) was 52%, compared to 52% in the second quarter of fiscal year 2023.
  • (1) Please see “Planet’s Use of Non-GAAP Financial Measures” below for a discussion on how Planet calculates the non-GAAP financial measures presented herein.
  • The actual amount of these expenses during the third quarter of fiscal year 2024 and fiscal year 2024 will have a significant impact on Planet’s future GAAP financial results.

SAB Launch Services awarded contract to launch two ICEYE SAR satellites

Retrieved on: 
Tuesday, September 20, 2022

We are excited to be launching a pair of our SAR satellites in early 2023 and to continuously grow our SAR constellation, said Alos Leptre, Launch Manager at ICEYE.

Key Points: 
  • We are excited to be launching a pair of our SAR satellites in early 2023 and to continuously grow our SAR constellation, said Alos Leptre, Launch Manager at ICEYE.
  • This agreement shows the appreciation from commercial customers for VEGA Services, including those used to take advantage of Non-European launch services in the past.
  • (SAB-LS) is a company part of SAB group offering launch services on European Launchers for all kind of Small Satellites.
  • SAB-LS offers end to end services including launch procurement, separation system procurement, integration activities of the satellite on the launch vehicle structure, In-Orbit Services, pre- and post-launch support.

Groundbreaking CAP Guideline Clarifies Biomarker Testing, Impacts Multiple Cancer Types

Retrieved on: 
Wednesday, August 3, 2022

The CAP developed the guideline in collaboration with experts from the Association for Molecular Pathology (AMP), the American Society of Clinical Oncology (ASCO), and the patient advocacy group Fight Colorectal Cancer (Fight CRC).

Key Points: 
  • The CAP developed the guideline in collaboration with experts from the Association for Molecular Pathology (AMP), the American Society of Clinical Oncology (ASCO), and the patient advocacy group Fight Colorectal Cancer (Fight CRC).
  • The new CAP guideline helps to fill that gap, providing oncologists, pathologists, and laboratories of all sizes with objective, evidence-based recommendations to efficiently deploy specific assays and accurately identify patients eligible for treatment.
  • To ensure patients receive more effective testing with consistent, high-quality results, and expert interpretations, the CAP provides free, open access tools and resources with each evidence-based guideline to help clinical and laboratory teams adopt the recommendations.
  • For more information, READ THE CAP ANNUAL REPORT at CAP.ORG.

Microsatellite Stable Colorectal Cancer Epidemiology Report 2022: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan 2019-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022

The Microsatellite Stable Colorectal Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.

Key Points: 
  • The Microsatellite Stable Colorectal Cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The Microsatellite Stable Colorectal Cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.
  • The Microsatellite Stable Colorectal Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032.
  • The Microsatellite Stable Colorectal Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Microsatellite Stable Colorectal Cancer Epidemiology Report and Model provide an overview of the global trends of Microsatellite Stable Colorectal Cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Microsatellite Stable Colorectal Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

Retrieved on: 
Tuesday, December 21, 2021

The top line clinical data from both the bladder and MSI-Hi cohorts are promising, further showcasing the potential of MVP-S as an immune-educating therapy in multiple cancer indications, said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV.

Key Points: 
  • The top line clinical data from both the bladder and MSI-Hi cohorts are promising, further showcasing the potential of MVP-S as an immune-educating therapy in multiple cancer indications, said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV.
  • A more complete set of data, including evaluation of PD-L1 and other measures will be presented at an upcoming scientific conference.
  • The study was designed to assess primary endpoints of safety and objective response rate (ORR), with multiple secondary and exploratory measures.
  • IMV enrolled 131 patients across clinical sites in the U.S. and Canada.